CJC-1295 without DAC + Ipamorelin – Synergistic GH Research Peptide Blend
The CJC-1295 without DAC + Ipamorelin Blend is a combined
research peptide formulation designed to study the
stimulation of growth hormone (GH) release through multiple
complementary mechanisms. This blend combines
CJC-1295 without DAC, a GHRH analogue that supports the
physiological pulsatile release of growth hormone, with Ipamorelin,
a GHRP that acts on the ghrelin receptor (GHSR),
creating a synergistic research model.
This peptide combination is manufactured according to high laboratory standards
and verified using High-Performance Liquid Chromatography (HPLC) to ensure
a purity of ≥ 99%. The blend is supplied exclusively for controlled
endocrinological and biochemical research under in-vitro conditions.
Blend composition
-
CJC-1295 without DAC – 5 mg:
Studied for its role in supporting the natural pulsatile release of
growth hormone via the GHRH receptor. -
Ipamorelin – 5 mg:
Investigated for its selective activation of the
ghrelin receptor (GHSR), without significant interaction with
cortisol or prolactin pathways in research models.
Key specifications
| Specification | Value / description |
|---|---|
| Name | CJC-1295 without DAC + Ipamorelin Blend |
| Total content | 10 mg (5 mg CJC-1295 without DAC + 5 mg Ipamorelin) |
| Type | Combination of GHRH and GHRP analogues |
| Form | Lyophilized powder |
| Purity | ≥ 99% (HPLC tested) |
| Storage conditions | Store refrigerated, protected from light and moisture |
Application & use (research only)
- Intended exclusively for in-vitro research purposes.
- Not suitable for human or veterinary consumption or medical use.
- Applicable to endocrinological research on growth hormone regulation and ghrelin receptor activity.
- Lyophilized form supports stable storage and controlled laboratory handling.
